Inclusion Criteria

INCLUSION CRITERIA:

- Disease criteria: This trial is primarily designed for: 1) patients with relapsed or
primary refractory non-Hodgkin's lymphoma, 2) chemosensitive relapsed or refractory
acute and chronic lymphocytic leukemias, 3) relapsed or primary refractory Hodgkin's
Disease, or advanced (Durie-Salmon stage II or III) multiple myeloma, advanced
Waldenstrom macroglobulinemia, who, by virtue of advanced age, intensity of prior
radiation and/or chemotherapy, history of prior toxicity associated with
chemo/radiotherapy or existing organ dysfunction, would be at undue risk of regimen
associated mortality if transplanted according to protocols involving myeloablative
conditioning regimens.

- Patients with aggressive NHL histologies must have chemo/radiosensitive disease, or
have non-progressive disease, or have stable disease on therapy, and be ineligible
for an autologous HSC transplant because of disease in the marrow.

- Patients with chronic myeloid leukemia and high risk forms of acute myelogenous
leukemia or myelodysplastic syndromes are also eligible in the absence of an
alternative active higher priority allogeneic transplant protocol for which they are
eligible.

- Age criteria: Patients may be up to 70 years of age. There is no lower age threshold.
Patients above the age of 70 may also participate, after evaluation and approval by
the BMT Service attendings.

- Absence of active or uncontrolled bacterial, viral, or fungal infection that would
contraindicate the use of myelosuppressive chemotherapy.

- Patients must have a healthy HLA-compatible donor, either a matched or single HLA
allele disparate related donor or a similarly compatible unrelated donor recruited
through the National Marrow Donor Program. Related donors must be willing to
participate as research subjects and be willing to receive G-CSF to mobilize PBPC and
undergo leukapheresis to donate PBSC. Unrelated donors identified by the NMDP may
elect to donate either PBSC after treatment with G-CSF, or bone marrow. These
unrelated donors will provide informed consent and their PBSC or bone marrow
donations will be obtained at a qualified donor center participating in the NMDP.

- Each patient must be willing to participate as a research subject and must sign an
informed consent form after discussion of the nature and risks of the study prior to
entering the protocol. Parents or legal guardians of patients who are minors will
sign the consent form for these patients after discussion of the nature and risks of
the study.

EXCLUSION CRITERIA:

- Female patients who are pregnant or lactating.

- Active or uncontrolled viral (including HIV-1), bacterial or fungal infection.

- Severe renal insufficiency (creatinine >2.0 or creatinine clearance < 30mL/minute)

- Severe hepatic dysfunction, as defined by: total bilirubin greater than 2.5 mg/dL and
AST and ALT >3xnl, unless the liver is involved with disease.

- Severe cardiac insufficiency, defined as a resting left ventricular ejection of less
than 30% as measured by echocardiography or radionuclide cardiac angiography.
Patients on cardiac medications for congestive heart failure are eligible, as long as
their LVEF is greater than 30% on medication.

- Severe pulmonary insufficiency, as defined by an adjusted diffusing capacity of less
than 40% of predicted value.

- Karnofsky or Lansky score <40%